Surinder Pal, MD
Internal Medicine · Ardsley, NYNPI 1538245139
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Avanir Pharmaceuticals, Inc. accounts for 77.4% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $193 and has fallen 82.2% since, to $34 in 2025. That places this record below the midpoint for internal medicine clinicians in NY, where the typical reported total is $194.
Across 21 payments — averaging $11.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$193
- Acadia Pharmaceuticals Inc$56
What the payments were for
- Food & beverage$249100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | 19 | $193 |
| Acadia Pharmaceuticals Inc | 2 | $56 |
How this compares
$249 in reported general payments places this provider in the 50th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,169 | $343,788 |
| JardianceEmpagliflozin | 252 | $77,027 |
| EntrestoSacubitril/Valsartan | 207 | $69,446 |
| AustedoDeutetrabenazine | 15 | $66,549 |
| SantylCollagenase Clostridium Hist. | 116 | $66,486 |
| OzempicSemaglutide | 49 | $50,716 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 14 | $50,383 |
| ZerbaxaCeftolozane/Tazobactam | 19 | $47,581 |
| JanuviaSitagliptin Phosphate | 156 | $42,743 |
| TivicayDolutegravir Sodium | 23 | $38,942 |
| Invega SustennaPaliperidone Palmitate | 15 | $36,843 |
| TradjentaLinagliptin | 117 | $31,184 |
| TrulicityDulaglutide | 51 | $29,611 |
| RexultiBrexpiprazole | 24 | $29,308 |
| XareltoRivaroxaban | 112 | $26,392 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Ardsley
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.